Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Multiplex Immunofluorescence Image Quality Checking Using DAPI Channel–referenced Evaluation
Moore, Raymond M. , Jordan, Clarissa E. , Guo, Ruifeng , Maus, Rachel L.G., Goode, Ellen L. , Wang, Chen , Jiang, Jun , Moore, Raymond , Maus, Rachel L, Wang, Chen , Guo, Ruifeng , Jiang, Jun , Liu, Hongfang , Markovic, Svetomir N.

Mayo Clinic

Journal of Histochemistry & Cytochemistry | March 24, 2023 | Volume: 71 | Issue: 3 | Pages: 121-130

10.1369/00221554231161693 | PMID 36960831 Get It

Multiplex immunofluorescence (MxIF) images provide detailed information of cell composition and spatial context for biomedical research. However, compromised data quality could lead to research biases. Comprehensive image quality checking (QC) is essential for reliable downstream analysis. As a reliable and specific staining of cell nuclei, 4′,6-diamidino-2-phenylindole (DAPI) signals were used as references for tissue localization and auto-focusing across MxIF staining–scanning–bleaching iterations and could potentially be reused for QC. To confirm the feasibility of using DAPI as QC reference, pixel-level DAPI values were extracted to calculate signal fluctuations and tissue content similarities in staining–scanning–bleaching iterations for identifying quality issues. Concordance between automatic quantification and human experts’ annotations were evaluated on a data set consisting of 348 fields of view (FOVs) with 45 immune and tumor cell markers. Cell distribution differences between subsets of QC-pass vs QC-failed FOVs were compared to investigate the downstream effects. Results showed that 87.3% FOVs with tissue damage and 73.4% of artifacts were identified. QC-failed FOVs showed elevated regional gathering in cellular feature space compared with the QC-pass FOVs. Our results supported that DAPI signals could be used as references for MxIF image QC, and low-quality FOVs identified by our method must be cautiously considered for downstream analyses.
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Köbel, Martin , Kang, Eunyoung , Weir, Ashley , Rambau, Peter , Nelson, Gregg , Meagher, Nicola S. , Riggan, Marjorie J. , Alsop, Jennifer , Anglesio, Michael S. , Beckmann, Matthias W. , Bisinotto, Christiani, Boisen, M.M. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , Deen, Suha , El‐Bahrawy, Mona , Group, AOCS, Fischer, Anna , Gayther, Simon A. , Hartmann, Arndt, Hendley, Joy , Huang, Yajue, Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Kluz, Tomasz , Koziak, Jennifer M. , Lesnock, Jaime, Lester, Jenny , Longacre, Teri A. , Lycke, Maria , Mateoiu, Constantina , McCauley, Bryan M. , McGuire, Valerie , Ney, Britta, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Paz‐Ares, Luis , Rothstein, Joseph H. , Ruebner, Matthias , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Talhouk, Aline , Whittemore, Alice S. , Widschwendter, Martin , Bowtell, David D.L. , Reis, Francisco José Cândido dos , Fasching, Peter A. , García, María J. , Goodman, Marc T. , Goode, Ellen L. , Huntsman, David G. , Kelemen, Linda E. , Kommoss, Stefan , Le, Nhu D. , Menon, Usha , Schildkraut, Joellen M. , Sieh, Weiva , Staebler, Annette , Ramus, Susan J. , Anglesio, Michael S , Erber, Ramona , Gilks, C. Blake , Shvetsov, Yurii B , Campbell, Ian G , Huntsman, David G , Ramus, Susan J , Köbel, Martin , Menon, Usha , Kennedy, Catherine J , Widschwendter, Martin , Jones, Michael E , Sieh, Weiva , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Kluz, Tomasz , Goodman, Marc T , Kang, Eun‐Young, Lee, Cheng‐Han , Ghatage, Prafull , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Fereday, Sián , Group, AOCS, Barquín, Arántzazu , Gentry‐Maharaj, Aleksandra , Gronwald, Helena , Grube, Marcel , Harnett, Paul R. , Harris, Holly R. , Hartkopf, Andreas D , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Lubiński, Jan , Cajal, Teresa Ramón y , Schoemaker, Minouk J. , Sherman, Mark E. , Steed, Helen , Storr, Sarah J. , Traficante, Nadia , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , Campbell, Ian , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Martin, Stewart G. , Modugno, Francesmary , Pharoah, Paul D.P. , Sundfeldt, Karin , Swerdlow, Anthony J. , Brenton, James D.

Mayo Clinic

The Journal of Pathology: Clinical Research | March 22, 2023 | Volume: 9 | Issue: 3 | Pages: 208-222

10.1002/cjp2.311 | PMID 36948887 Get It

AbstractOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi‐institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36–3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11–2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, Jamie M. , Helzer, Kyle T. , Stahlfeld, Charlotte N. , Jiang, Dawei , Singh, Anupama , Kaufmann, Katherine R. , Niles, David J. , Héninger, Erika , Rydzewski, Nicholas R. , Wang, Liguo , Wang, Liewei , Yang, Rendong , Ren, Yanan , Kyriakopoulos, Christos E. , Slovin, Susan F. , Soule, Howard R. , Zhao, Shuang G. , Cai, Weibo , Dehm, Scott M. , Lang, Joshua M. , Engle, Jonathan W , Huang, Peng , Kyriakopoulos, Christos E , Slovin, Susan F , Soule, Howard R , Zhao, Shuang G , Kohli, Manish , Tagawa, Scott T , Cai, Weibo , Dehm, Scott M , Lang, Joshua M , Wang, Liguo , Engle, Jonathan W. , Kohli, Manish , Tagawa, Scott T.

Mayo Clinic

Clinical Cancer Research | March 20, 2023 | Volume: 29 | Issue: 12 | Pages: 2324-2335

10.1158/1078-0432.ccr-22-1305 | PMID 36939530 Get It

Abstract Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC). Experimental Design: TROP-2 gene (TACSTD2) expression and markers of treatment resistance from prostate biopsies were analyzed using data from four previously curated cohorts of mCRPC (n = 634) and the PROMOTE study (dbGaP accession phs001141.v1.p1, n = 88). EPCAM or TROP-2–positive circulating tumor cells (CTC) were captured from peripheral blood for comparison of protein (n = 15) and gene expression signatures of treatment resistance (n = 40). We assessed the efficacy of TROP-2–targeting agents in a mouse xenograft model generated from prostate cancer cell lines. Results: We demonstrated that TACSTD2 is expressed in mCRPC from luminal and basal tumors but at lower levels in patients with neuroendocrine prostate cancer. Patients previously treated with ARSI showed no significant difference in TACSTD2 expression, whereas patients with detectable AR-V7 expression showed increased expression. We observed that TROP-2 can serve as a cell surface target for isolating CTCs, which may serve as a predictive biomarker for ADCs. We also demonstrated that prostate cancer cell line xenografts can be targeted specifically by labeled anti–TROP-2 agents in vivo. Conclusions: These results support further studies on TROP-2 as a therapeutic and diagnostic target for mCRPC.
Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions
Lindström, Sara , Wang, Lu , Feng, Helian , Huo, Sijia , Harrison, Tabitha A. , Turman, Constance , Chen, Hongjie , Bammler, Theo K. , Gallinger, Steve, Gruber, Stephen B. , Moreno, Vı́ctor , Offit, Kenneth , O’Mara, Tracy A. , Tomlinson, Ian, Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Bondy, Melissa L. , Houlston, Richard S. , Jenkins, Robert B. , Melin, Beatrice , Wrensch, Margaret , Brennan, Paul , Johansson, Mattias , McKay, James , Aldrich, Melinda C. , Landi, Maria Teresa , Bishop, D. Timothy , Iles, Mark M. , Law, Matthew H. , Wolpin, Brian M. , Petersen, Gloria M. , Purdue, Mark P. , Scélo, Ghislaine , Kar, Siddhartha , Hung, Rayjean J, Kraft, Peter , Lissowska, Jolanta , Simard, Jacques , Dörk, Thilo , John, Esther M. , Carracedo, Ángel , Huang, Wen‐Yi , Vodička, Pavel , Taylor, Jack A. , Lessel, Davor , Kurian, Allison W. , Hung, Rayjean J. , Kundaje, Anshul , Zhong, Jun , Turman, Constance , Chen, Hongjie , Gruber, Stephen B , Marchand, Loïc Le , Moreno, Victor , Offit, Kenneth , Gharahkhani, Puya , MacGregor, Stuart , Schumacher, Johannes , Houlston, Richard S , Brennan, Paul , Johansson, Mattias , Iles, Mark M , Law, Matthew H , Amundadottir, Laufey , Klein, Alison P , Petersen, Gloria, Chanock, Stephen Jacob , Kar, Siddhartha , Kraft, Peter , Dörk, Thilo , Lissowska, Jolanta , John, Esther M , Hung, Rayjean J , Harrison, Tabitha A , O'Mara, Tracy A , Lessel, Davor , Bishop, D Timothy , Huang, Wen-Yi , Taylor, Jack A , Simard, Jacques , Kurian, Allison W , Kundaje, Anshul , Vodicka, Pavel , Zhong, Jun , Majumdar, Arunabha , MacDonald, James W. , Mancuso, Nicholas , Gunter, Marc J. , Marchand, Loı̈c Le , Vivo, Immaculata De , Spurdle, Amanda B. , Fitzgerald, Rebecca C. , Gockel, Ines , Jankowski, Janusz , Barnholtz‐Sloan, Jill S. , Christiani, David C. , Amos, Christopher I. , Tardón, Adonina , Démenais, Florence , Goldstein, Alisa M. , Kanetsky, Peter A. , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Risch, Harvey A. , Pharoah, Paul D.P. , Paşaniuc, Bogdan

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 17, 2023 | Volume: 115 | Issue: 6 | Pages: 712-732

10.1093/jnci/djad043 | PMID 36929942 Get It

Abstract Background The shared inherited genetic contribution to risk of different cancers is not fully known. In this study, we leverage results from 12 cancer genome-wide association studies (GWAS) to quantify pairwise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci. Methods We collected GWAS summary statistics for 12 solid cancers based on 376 759 participants with cancer and 532 864 participants without cancer of European ancestry. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. We conducted cross-cancer GWAS and transcriptome-wide association studies to discover novel cancer susceptibility loci. Finally, we assessed the extent of variant-specific pleiotropy among cancers at known and newly identified cancer susceptibility loci. Results We observed widespread but modest genome-wide genetic correlations across cancers. In cross-cancer GWAS and transcriptome-wide association studies, we identified 15 novel cancer susceptibility loci. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least 2 cancer types by testing for pleiotropy at known cancer susceptibility loci. Conclusions Overall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer-specific and thus tissue-specific. The increase in statistical power associated with larger sample sizes in cross-disease analysis allows for the identification of novel susceptibility regions. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types.
Association of abnormal p‐wave parameters with brain MRI morphology: The atherosclerosis risk in communities neurocognitive study (ARIC‐NCS)*
Reyes, Jorge L. , Norby, Faye L. , Ji, Yuekai, Wang, Wendy , Parikh, Romil R , Zhang, Michael J. , Oldenburg, Niki , Lutsey, Pamela L. , Johansen, Michelle C. , Soliman, Elsayed Z. , Alonso, Álvaro , Alonso, Alvaro , Zhang, Michael , Lutsey, Pamela L , Johansen, Michelle C , Parikh, Romil R , Jack, Clifford R. , Gottesman, Rebecca F. , Coresh, Josef , Mosley, Thomas H. , Chen, Lin Y.

Mayo Clinic

Pacing and Clinical Electrophysiology | March 16, 2023 | Volume: 46 | Issue: 8 | Pages: 951-959

10.1111/pace.14687 | PMID 36924350 Get It

AbstractBackgroundRecent evidence indicates that abnormal P‐wave parameters (PWPs)—ECG markers of atrial myopathy—are associated with incident dementia, independent of atrial fibrillation (AF) and clinical ischemic stroke. However, the mechanisms remain unclear and may include subclinical vascular brain injury. Hence, we evaluated the association of abnormal PWPs with brain MRI correlates of vascular brain injury in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC‐NCS).MethodsARIC‐NCS participants who underwent 3T brain MRI scans in 2011–2013 were included. PWPs were measured from standard 12‐lead ECGs. Brain MRI outcomes included cortical infarcts, lacunar infarcts, cerebral microhemorrhages, brain volumes, and white matter disease (WMD) volume. We used weighted multivariable logistic and linear regression to evaluate the associations of abnormal PWPs with brain MRI outcomes.ResultsAmong 1715 participants (mean age, 76.1 years; 61% women; 29% Black), 797 (46%) had ≥1 abnormal PWP. After multivariable adjustment, including adjusting for prevalent AF, abnormal P‐wave terminal force in lead V1 (aPTFV1) and prolonged P‐wave duration (PPWD) were associated with increased odds of both cortical (OR 1.41; 95% CI, 1.14 to 1.74 and OR 1.30; 95% CI, 1.04 to 1.63, respectively) and lacunar infarcts (OR 1.36; 95% CI, 1.15 to 1.63 and OR 1.37; 95% CI, 1.15 to 1.65, respectively). Advanced interatrial block (aIAB) was associated with higher odds of subcortical microhemorrhage (OR 2.04; 95% CI, 1.36 to 3.06). Other than a significant association between aPTFV1 with lower parietal lobe volume, there were no other significant associations with brain or WMD volume.ConclusionIn this exploratory analysis of a US community‐based cohort, ECG surrogates of atrial myopathy are associated with a higher prevalence of brain infarcts and microhemorrhage, suggesting subclinical vascular brain injury as a possible mechanism underlying the association of atrial myopathy with dementia.
Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration‐resistant prostate cancer
Lewis, Akeem R. , Costello, Brian A. , Pagliaro, Lance C. , Sanhueza, Cristobal T., Weinshilboum, Richard M. , Wang, Liewei , Tan, Winston , Quevedo, Fernando , Quevedo, Fernando , Weinshilboum, Richard M. , Kalari, Krishna R. , Kohli, Manish , Giridhar, Karthik V.

Mayo Clinic

The Prostate | March 16, 2023 | Volume: 83 | Issue: 7 | Pages: 649-655

10.1002/pros.24498 | PMID 36924119 Get It

AbstractObjectiveElevated serum chromogranin A (CGA) is associated with intrinsic or treatment‐related neuroendocrine differentiation (NED) in men with metastatic castration‐resistant prostate cancer (mCRPC). Fluctuations in serum CGA during treatment of mCRPC have had conflicting results. We analyzed the impact of (i) rising serum CGA and (ii) baseline CGA/PSA ratio during treatment to identify associations with abiraterone acetate (AA) therapy.MethodsBetween June 2013 and August 2015, 92 men with mCRPC were enrolled in a prospective trial with uniform serum CGA processing performed before initiating abiraterone acetate/prednisone (AA/P) and serially after 12 weeks of AA/P treatments. Serum CGA was measured using a homogenous automated immunofluorescent assay. Patients receiving proton pump inhibitors or with abnormal renal function were excluded due to possible false elevations of serum CGA (n = 21 excluded), therefore 71 patients were analyzed. All patients underwent a composite response assessment at 12‐weeks. Kaplan–Meier estimates and Cox Regression models were used to calculate the association with time‐to‐treatment failure analyses and overall survival.ResultsAn increase in chromogranin was associated with a lower risk of treatment failure (hazard ratio [HR]: 0.52, p = 0.0181). The median CGA/PSA ratio was 7.8 (2.6–16.0) and an elevated pretreatment CGA/PSA ratio above the median was associated with a lower risk of treatment failure (HR: 0.54 p value = 0.0185). An increase in CGA was not found to be associated with OS (HR: 0.71, 95% CI: 0.42–1.21, p = 0.207). An elevated baseline CGA/PSA ratio was not associated with OS (HR: 0.62, 95% CI: 0.37–1.03, p = 0.062). An increase in PSA after 12 weeks of treatment was associated with an increased risk of treatment failure (HR: 4.14, CI: 2.21–7.73, p = < 0.0001) and worse OS (HR: 2.93, CI: 1.57–4.45, p = < 0.0001).ConclusionsWe show that an increasing chromogranin on AA/P and an elevated baseline CGA/PSA in patients with mCRPC were associated with a favorable response to AA/P with no changes in survival. There may be limited clinical utility in serum CGA testing to evaluate for lethal NED as AA/P did not induce lethal NED in this cohort. This highlights that not all patients with an increasing CGA have a worse OS.
Sleep Disturbances in Cervical Spondylotic Myelopathy
Bisson, Erica F. , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Chan, Andrew K. , Agarwal, Nitin , Wang, Michael Y. , Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Than, Khoi D. , Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Shabani, Saman , Glassman, Steven D. , Tumialan, Louis M., Turner, Jay D. , Uribe, Juan S. , Meyer, Scott A., Lu, Daniel C. , Buchholz, Avery L., Upadhyaya, Cheerag D., Shaffrey, Mark E., Park, Paul , Foley, Kevin T. , Coric, Domagoj , Slotkin, Jonathan R., Potts, Eric A. , Stroink, Ann R., Chou, Dean , Fu, Kai-Ming, Haid, Regis W., Asher, Anthony L. , Bydon, Mohamad , Uribe, Juan S. , El Sammak, Sally, Michalopoulos, Giorgos , Sammak, Sally El , Goldberg, Jacob L.

Mayo Clinic

Clinical Spine Surgery | March 15, 2023 | Volume: 36 | Issue: 3 | Pages: 112-119

10.1097/bsd.0000000000001454 | PMID 36920372 Get It

Study Design: Prospective observational study, level of evidence 1 for prognostic investigations. Objectives: To evaluate the prevalence of sleep impairment and predictors of improved sleep quality 24 months postoperatively in cervical spondylotic myelopathy (CSM) using the quality outcomes database. Summary of Background Data: Sleep disturbances are a common yet understudied symptom in CSM. Materials and Methods: The quality outcomes database was queried for patients with CSM, and sleep quality was assessed through the neck disability index sleep component at baseline and 24 months postoperatively. Multivariable logistic regressions were performed to identify risk factors of failure to improve sleep impairment and symptoms causing lingering sleep dysfunction 24 months after surgery. Results: Among 1135 patients with CSM, 904 (79.5%) had some degree of sleep dysfunction at baseline. At 24 months postoperatively, 72.8% of the patients with baseline sleep symptoms experienced improvement, with 42.5% reporting complete resolution. Patients who did not improve were more like to be smokers [adjusted odds ratio (aOR): 1.85], have osteoarthritis (aOR: 1.72), report baseline radicular paresthesia (aOR: 1.51), and have neck pain of ≥4/10 on a numeric rating scale. Patients with improved sleep noted higher satisfaction with surgery (88.8% vs 72.9%, aOR: 1.66) independent of improvement in other functional areas. In a multivariable analysis including pain scores and several myelopathy-related symptoms, lingering sleep dysfunction at 24 months was associated with neck pain (aOR: 1.47) and upper (aOR: 1.45) and lower (aOR: 1.52) extremity paresthesias. Conclusion: The majority of patients presenting with CSM have associated sleep disturbances. Most patients experience sustained improvement after surgery, with almost half reporting complete resolution. Smoking, osteoarthritis, radicular paresthesia, and neck pain ≥4/10 numeric rating scale score are baseline risk factors of failure to improve sleep dysfunction. Improvement in sleep symptoms is a major driver of patient-reported satisfaction. Incomplete resolution of sleep impairment is likely due to neck pain and extremity paresthesia.